<DOC>
	<DOC>NCT02351856</DOC>
	<brief_summary>This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion, derive benefit from continued treatment.</brief_summary>
	<brief_title>A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy, Dilated</mesh_term>
	<criteria>Key Received ARRY371797 as treatment for a genetic dilated cardiomyopathy secondary to LMNA mutations in a clinical study sponsored by Array BioPharma. May, in the opinion of the Investigator, benefit from continued ARRY371797 treatment. Additional criteria exist. Key Discontinued treatment in the parent study for any reason other than study completion or Sponsor termination of the study. Additional criteria exist.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>laminopathy</keyword>
</DOC>